stockrowRevolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
Follow RVMD
Alert me
Revolution Medicines, Inc. (RVMD) Return on equity
Revolution Medicines, Inc.'s return on equity over the twelve months to 30 September 2026 was −93.6%, down 35.5 percentage points from fiscal 2025 (−58.1%). Over the past ten years it has ranged from −68.5% (fiscal 2020) to 55.4% (fiscal 2018); the current reading is higher than 22% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −58.1% | (28.74) |
| FY2024 | −29.3% | 5.42 |
| FY2023 | −34.8% | 3.88 |
| FY2022 | −38.6% | (3.89) |
| FY2021 | −34.7% | 33.80 |
| FY2020 | −68.5% | (115.98) |
| FY2019 | 47.4% | (7.99) |
| FY2018 | 55.4% | 15.81 |
| FY2017 | 39.6% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 18.4% |
| GMAB Genmab A/S Sponsored ADR compare | 14.0% |
| INCY Incyte Corporation compare | 7.84% |
| ARGX argenex SE compare | 0.00% |
| RPRX Royalty Pharma PLC compare | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −5.47% |
| BNTX BioNTech SE Sponsored ADR compare | −8.29% |
| INSM Insmed, Inc. compare | −72.5% |
| RVMD Revolution Medicines, Inc. | −93.6% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on RVMD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement